Tanios S. Bekaii-Saab, MD, gives an overview of the presentation trends and molecular testing practices for metastatic colorectal cancer.
Back
Post-Conference Perspectives: Updates in HER2+ Metastatic Colorectal Cancer (mCRC); ASCO 2023 Highlights
Following the 2023 ASCO Annual Meeting, Tanios S. Bekaii-Saab, MD, discusses recent data updates and provides clinical insights on the evolving treatment landscape for metastatic colorectal cancer.
Post-Conference Perspectives: Updates in HER2+ Metastatic Colorectal Cancer (mCRC); ASCO 2023 Highlights
Episodes
All
All
An expert on colorectal cancer discusses the relationship between HER2 status and treatment selection and response.
Tanios S. Bekaii-Saab, MD, discusses recent clinical trials and provides insights on the evolving metastatic colorectal cancer treatment landscape.
An overview of the DESTINY-CRC02 study, which looked at trastuzumab deruxtecan in patients with HER2+ metastatic colorectal cancer.
Tanios S. Bekaii-Saab, MD, offers closing thoughts on the unmet needs and future of HER2+ metastatic colorectal cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
5